I believe that Deb, who started this thread, is SVR now - if that helps. She was an acute patient when she treated though.
True geno4 usually treats the same as geno1 - better safe than sorry. Definitely.
Conclusion
In conclusion, the authors write, “In patients with chronic hepatitis C genotype 4, once-weekly peginterferon alfa-2b plus ribavirin was tolerated and produced significant improvements in the rate of sustained virologic response, as well as histological response.”
“Patients with HCV genotype 4 seem to be adequately treated with peginterferon alfa-2b plus ribavirin for 36 weeks.”
Genotype 4 may be more responsive to treatment than genotype 1. Sustained virological response rates from two studies that used 48 weeks of pegylated interferon plus ribavirin have ranged from 40% to 61% (Esmat 2003; Hassan 2003).
Genotypes 1 and 4 do not respond to treatment as well as genotypes 2 and 3, regardless of the type of interferon used (Berg 2003; Fried 2002a; S. Lee 2002; McHutchison 1998
http://www.janis7hepc.com/genotype_research_2007.htm
Hi, I just found this old post. I am Genotype 4 i'm from so Ca, I haven't did any Tx yet stage 1 Grade 1. Just supplements and diet. Have you any updated news?
Have you been to the Janis web site? I'm a geno 2, I'm sure we have other 4's here. I figure you're looking more for a genotype comrad tnan info on the geno type but Janis and friends has a lot of great info on hep C.
http://janis7hepc.com/2005_genotype_research1.htm#tr
I don't think there are that many around! I did find this on geno 4, kind of interesting.
"The aim of this study was to assess changes in the prevalence of hepatitis C virus (HCV) genotypes, focusing on genotype 4, by surveying population of chronic hepatitis C patients within an area of Southern Italy. HCV-RNA was detected in serum using two commercial hepatitis C RNA PCR assays (Amplicor Roche Diagnostic System, and AmpliSensor HCV, Nuclear Laser Medicine). PCR products were analyzed for genotyping using a reverse hybridization of the amplified product by a line probe assay (INNO LIPA, Innogeneties). In our Institution we have previously observed, in a period of IX months (January 1997-May 1998) an initial increase of the genotype 4 which appeared in 3.3% of HCV patients versus a percentage of 1.3%, during 1996, Later data obtained from 702 HCV-RNA positive patients, collected from June 1998 until December 1999 indicated a 3.7% of genotype 4. This percentage increased until to 4.7% in the most recent period studied (January 2000-February 2001) Drug addictions blood transfusion and sporadically acquired infections represented the most frequent risk factors. In the Calabria region, genotype 1b, the most prevalent isolate (53.3%) and genotype 2a/2c (26.2%) were associated with older age, confirming our previous study. Genotype 4 was the fifth most prevalent genotype observed, just after 3a and 1a subtypes. Spread of genotype 4 in Calabria region is mostly associated to older age when compared to genotype 3a and 1a, but is statistically associated with a younger group of patients when compared with genotype 1b. In conclusion we demonstrated a fourfold increased prevalence of HCV genotype 4 during the last 5 years."